The Contact Dermatitis market report provides current treatment practices, emerging drugs, Contact Dermatitis market share of the individual therapies, current and forecasted Contact Dermatitis market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Contact Dermatitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2020-2034
Contact Dermatitis Disease Understanding and Treatment Algorithm
The Contact Dermatitis market report gives a thorough understanding of the Contact Dermatitis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Contact Dermatitis.Treatment
It covers the details of conventional and current medical therapies available in the Contact Dermatitis market for the treatment of the condition. It also provides Contact Dermatitis treatment algorithms and guidelines in the United States, Europe, and Japan.Contact Dermatitis Epidemiology
The Contact Dermatitis epidemiology division provide insights about historical and current Contact Dermatitis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Contact Dermatitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.Country Wise-Contact Dermatitis Epidemiology
The epidemiology segment also provides the Contact Dermatitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.Contact Dermatitis Drug Chapters
Drug chapter segment of the Contact Dermatitis report encloses the detailed analysis of Contact Dermatitis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Contact Dermatitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.Marketed Drugs
The report provides the details of the marketed product available for Contact Dermatitis treatment.Contact Dermatitis Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Contact Dermatitis treatment.Contact Dermatitis Market Outlook
The Contact Dermatitis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Contact Dermatitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.This segment gives a thorough detail of Contact Dermatitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, Contact Dermatitis market in 7MM is expected to change in the study period 2020-2034.
Key Findings
This section includes a glimpse of the Contact Dermatitis market in 7MM.The United States Market Outlook
This section provides the total Contact Dermatitis market size and market size by therapies in the United States.EU-5 Countries: Market Outlook
The total Contact Dermatitis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.Japan Market Outlook
The total Contact Dermatitis market size and market size by therapies in Japan is also mentioned.Contact Dermatitis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Contact Dermatitis market or expected to get launched in the market during the study period 2020-2034. The analysis covers Contact Dermatitis market uptake by drugs; patient uptake by therapies; and sales of each drug.This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Contact Dermatitis Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Contact Dermatitis key players involved in developing targeted therapeutics.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Contact Dermatitis emerging therapies.Reimbursement Scenario in Contact Dermatitis
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.KOL- Views
To keep up with current market trends, we take KOLs and SME's opinion working in Contact Dermatitis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Contact Dermatitis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Contact Dermatitis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.Scope of the Report
- The report covers the descriptive overview of Contact Dermatitis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Contact Dermatitis epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Contact Dermatitis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Contact Dermatitis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Contact Dermatitis market
Report Highlights
- In the coming years, Contact Dermatitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- Companies and academics are working to assess challenges and seek opportunities that could influence Contact Dermatitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- The major players are involved in developing therapies for Contact Dermatitis. Launch of emerging therapies will significantly impact the Contact Dermatitis market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Contact Dermatitis
- This in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Contact Dermatitis Report Insights
- Patient Population
- Therapeutic Approaches
- Contact Dermatitis Pipeline Analysis
- Contact Dermatitis Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Contact Dermatitis Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Contact Dermatitis Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Contact Dermatitis Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Questions
Market Insights:
- What was the Contact Dermatitis market share (%) distribution in 2020 and how it would look like in 2034?
- What would be the Contact Dermatitis total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Contact Dermatitis market size during the forecast period (2024-2034)?
- At what CAGR, the Contact Dermatitis market is expected to grow in 7MM during the forecast period (2020-2034)?
- What would be the Contact Dermatitis market outlook across the 7MM during the forecast period (2020-2034)?
- What would be the Contact Dermatitis market growth till 2032, and what will be the resultant market Size in the year 2034?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden and unmet needs of the Contact Dermatitis?
- What is the historical Contact Dermatitis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Contact Dermatitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Contact Dermatitis?
- Out of all 7MM countries, which country would have the highest prevalent population of Contact Dermatitis during the forecast period (2020-2034)?
- At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Contact Dermatitis treatment, along with the approved therapy?
- What are the current treatment guidelines for the treatment of Contact Dermatitis in the USA, Europe, and Japan?
- What are the Contact Dermatitis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Contact Dermatitis?
- How many therapies are developed by each company for Contact Dermatitis treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Contact Dermatitis treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Contact Dermatitis therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Contact Dermatitis and their status?
- What are the key designations that have been granted for the emerging therapies for Contact Dermatitis?
- What are the global historical and forecasted market of Contact Dermatitis?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Contact Dermatitis market
- To understand the future market competition in the Contact Dermatitis market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Contact Dermatitis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Contact Dermatitis market
- To understand the future market competition in the Contact Dermatitis market
Table of Contents
Executive Summary
Country Wise- Contact Dermatitis (CD) Epidemiology
The epidemiology segment also provides the Contact Dermatitis (CD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Contact Dermatitis (CD) Drug Chapters
The drug chapter segment of the Contact Dermatitis (CD) report encloses the detailed analysis of Contact Dermatitis (CD) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Contact Dermatitis (CD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Contact Dermatitis (CD) Emerging Drugs
EB01 Cream: Edesa Biotech
EB01 is a novel sPLA2 inhibitor for the topical treatment of chronic ACD. The sPLA2 inhibitors are designed to inhibit the inflammatory process at its inception rather than after inflammation has occurred. The drug inhibits sPLA2 from degrading phospholipids to produce arachidonic acid. Arachidonic acid is processed via the LOX-COX pathway to generate several pro-inflammatory signalling molecules. The drug exerts its anti-inflammatory activity upstream of currently approved NSAIDs, which target the LOX-COX pathway. The FDA accepted Edesa's investigational new drug (IND) application of EB01 for CD patients in November 2018. In June 2019, Edesa Biotech and Stellar Biotechnologies completed share exchange agreement. The combined company, called Edesa Biotech, thereafter, focused on the development and advancement of innovative treatments for dermatological and gastrointestinal indications. In December 2019, the company reported that EB01 had demonstrated positive safety data in healthy volunteers participating in its ongoing phase IIb clinical study in chronic ACD. Considering this positive result, the company expanded the phase IIb dermatitis study to patients with facial lesions. Currently, the drug is still being investigated in phase II clinical developmental trial in the United States for CD.
Product detail in the report…
PDC-APB: Hapten Sciences
PDC-APB is a small molecule that acts like a vaccine to prevent the excruciating itching and rash (CD) caused by exposure to urushiol (yoo-ROO-she-ol) oil in poison ivy, poison oak, and poison sumac plants. Hapten licensed PDC-APB from the University of Mississippi in 2010. In 2015, the company had filed an Investigational New Drug (IND) application of PDC-APB for CD caused by poison ivy, poison oak, and poison sumac plants. The drug has already completed its phase I trial in January 2018 and in June 2019, Hapten Sciences published data regarding attainment of a fourth patent by the University of Mississippi for its investigational product that could prevent the painful itching and rash due to exposure to poison ivy, poison oak, and poison sumac.
Product detail in the report…
Contact Dermatitis (CD) Market Outlook
According to the American Academy of Allergy Asthma and Immunology (AAAAI), the CD is a common skin problem that occurs in ~15-20% of people. It can pose a significant financial burden with direct and indirect costs from lost time off work and school. CD can either be of allergic (ACD) type or irritant (ICD) type. Out of these two, ICD is more common (80%) and can occur in anyone, especially after repeated exposure. Additionally, in 2004, the Society of Investigative Dermatology revealed that ~72.3 million people were suffering from CD in the United States, representing one of the top five most economically burdensome skin diseases.
Since there are no approved therapies for CD, the market is mainly dominated by the use of off-label prescription drugs. Treatments for CD include Topical Corticosteroids (Clobetasol and Triamcinolone) and Emollients, Topical Immunosupressants (Pimecromilus and Tacrolimus), Systemic Immunosupressants (Antihistamines) and Corticosteroids, and Others (Antiseptics, Topical Antibiotics, Phototherapy, and Other Immunosupressants). However, topical corticosteroids remain the mainstay or the first-line treatment option for CD while phototherapy and systemic immune modulators form the second-line treatment option for the indication.
The American Academy of Allergy, Asthma, and Immunology (AAAAI) has published separate diagnostic and management guidelines for both CD and atopic dermatitis (AD). As per these guidelines, the treatment pattern of both the indications was quite similar. Even though the pathophysiology of AD and CD are extremely different as AD is an immunodeficiency disorder and CD is contact triggered disorder, but the signs and symptoms of both the diseases are quite similar that justifies the same prescription pattern as well. Keeping this in mind, the US CD market forecast considers AD prescription pattern.
However, the current emerging market of CD does not possess a robust pipeline. There is only one therapy, EB01 Cream, which is in its phase II developmental stage. Additionally, there is another therapy, namely, PDC-APB that has completed its phase I trial and was licensed by Hapten from the University of Mississippi in 2010. The phase I trial of PDC-APB was completed in January 2018 itself; however, the results of this trial has not been published yet. Therefore, Hapten's PDC-APB has not been considered in the forecast model of CD report.
Key Findings
This section includes a glimpse of the Contact Dermatitis (CD) 7MM market.
- The market size of CD in the seven major markets was estimated to be USD 7,831 Million in 2017.
- The United States accounts for the largest market size of CD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
- Among the EU5 countries, Germany had the highest market size with USD 981 Million in 2017, while Spain had the lowest market size of CD with USD 293 Million in 2017.
- The Japan CD market accounted for USD 752 Million in 2017, which is expected to increase during the forecast period of 2020-2030.
The United States Market Outlook
This section provides the total Contact Dermatitis (CD) market size and market size by therapies in the United States.
EU-5 Market Outlook
The total aspregillosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Contact Dermatitis (CD) market size and market size by therapies in Japan are provided.
Contact Dermatitis (CD) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Contact Dermatitis (CD) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Contact Dermatitis (CD) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Contact Dermatitis (CD) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Contact Dermatitis (CD) emerging therapies.
Competitive Intelligence Analysis
The publisher performs competitive and market Intelligence analysis of the Contact Dermatitis (CD) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Contact Dermatitis (CD), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
- Comprehensive insight has been provided into the Contact Dermatitis (CD) epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Contact Dermatitis (CD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of Contact Dermatitis (CD) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Contact Dermatitis (CD) market.
Report Highlights
- In the coming years, Contact Dermatitis (CD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Contact Dermatitis (CD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- The publisher has analyzed type-based data for Contact Dermatitis (CD). Contact Dermatitis can be of two types based on this data, namely, Irritant Contact Dermatitis (ICD) and Allergic Contact Dermatitis (ACD).
- Type-specific data based on clinical and biological evolution of Contact Dermatitis (CD) has also been analyzed by the publisher. On this basis, Contact Dermatitis can be divided as Acute, Sub-acute and Chronic type.
- In addition, the publisher has also analyzed gender-specific data for Contact Dermatitis (CD), which clearly suggests that CD is more prevalent among females than males.
- The report also encompasses another major segment, i.e., Age-specific Diagnosed Prevalent Population of Contact Dermatitis (CD), wherein various age groups have been considered, such as 0-17, 18-29, 30-45, 46-60, 61-75 and 75+. It has been found that CD majorly affects patients whose age is 40 years or above.
- Expected Launch of a potential therapy, EB01 (Edesa Biotech), may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of Contact Dermatitis (CD).
- The current treatment of Contact Dermatitis (CD) is mainly dominated by the use of off-label therapies, which includes Topical Corticosteroids (Clobetasol and Triamcinolone) and Emollients, Topical Immunosupressants (Pimecromilus and Tacrolimus), Systemic Immunosupressants (Antihistamines) and Corticosteroids and Others (Antiseptics, Topical Antibiotics, Phototherapy and Other Immunosupressants).
Contact Dermatitis (CD) Report Insights
- Patient Population
- Therapeutic Approaches
- Contact Dermatitis (CD) Pipeline Analysis
- Contact Dermatitis (CD) Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Contact Dermatitis (CD) Report Key Strengths
- Eleven Years Forecast
- 7MM Coverage
- Contact Dermatitis (CD) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Contact Dermatitis (CD) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Questions Answered
Market Insights:
- What was the Contact Dermatitis (CD) market share (%) distribution in 2017 and how it would look like in 2030?
- What would be the Contact Dermatitis (CD) total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest Contact Dermatitis (CD) market size during the forecast period (2020-2030)?
- At what CAGR, the Contact Dermatitis (CD) market is expected to grow at the 7MM level during the forecast period (2020-2030)?
- What would be the Contact Dermatitis (CD) market outlook across the 7MM during the forecast period (2020-2030)?
- What would be the Contact Dermatitis (CD) market growth till 2030 and what will be the resultant market size in the year 2030?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden and unmet needs of Contact Dermatitis (CD)?
- What is the historical Contact Dermatitis (CD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
- What would be the forecasted patient pool of Contact Dermatitis (CD) at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Contact Dermatitis (CD)?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Contact Dermatitis (CD) during the forecast period (2020-2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the treatment of Contact Dermatitis (CD) along with the approved therapy?
- What are the current treatment guidelines for the treatment of Contact Dermatitis (CD) in the US and Europe?
- What are the Contact Dermatitis (CD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Contact Dermatitis (CD)?
- How many therapies are developed by each company for the treatment of Contact Dermatitis (CD)?
- How many emerging therapies are in the mid-stage and late stage of development for the treatment of Contact Dermatitis (CD)?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Contact Dermatitis (CD) therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Contact Dermatitis (CD) and their status?
- What are the key designations that have been granted for the emerging therapies for Contact Dermatitis (CD)?
- What are the 7MM historical and forecasted market of Contact Dermatitis (CD)?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the Contact Dermatitis (CD).
- To understand the future market competition in the asprgillosis market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Contact Dermatitis (CD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for Contact Dermatitis (CD) market.
- To understand the future market competition in the Contact Dermatitis (CD) market.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Edesa Biotech
- Hapten Sciences
